B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

NR3C2

MOLECULAR TARGET

nuclear receptor subfamily 3 group C member 2

UniProt: P08235NCBI Gene: 430615 compounds

NR3C2 (nuclear receptor subfamily 3 group C member 2) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting NR3C2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Eplerenone3.0921
2Spironolactone3.0019
3Aldosterone2.8917
4Prednisolone2.5612
5Progesterone2.208
6Hydrocortisone1.614
7Hydrocortisone1.614
8Budesonide1.393
9Dihydrotestosterone1.393
10Medroxyprogesterone Acetate1.393
11Canrenone0.691
12Corticosterone0.691
13Desoxycorticosterone0.691
14Fludrocortisone0.691
15withanolide a0.691

About NR3C2 as a Drug Target

NR3C2 (nuclear receptor subfamily 3 group C member 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented NR3C2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

NR3C2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.